Our Science – Bishop Website

Michael R. Bishop, M.D.

Selected Publications

1) Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Ann. Oncol. 2008. [Journal]

2) Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD.
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
Blood. Epub ahead of print, 2008. [Journal]

3) Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR, Giralt S, Horowitz MM, Weisdorf DJ.
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.
Bone Marrow Transplant. 41: 635-42, 2008. [Journal]

4) Marks DI, Perez WS, He W, Zhang M, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ.
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
Blood. 112: 426-34, 2008. [Journal]

5) Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT.
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Biol. Blood Marrow Transplant. 14: 290-300, 2008. [Journal]

6) Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M, Fontaine LS, Babb R, Bishop MR, Caporaso N, Marti GE.
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
Br. J. Haematol. 139: 824-31, 2007. [Journal]

7) Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett AJ, Bishop MR, Childs RW, Fowler DH, Pavletic SZ, Hart TC.
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
Exp. Hematol. 35: 184-92, 2007. [Journal]

8) Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh U, Bishop M, Barrett J, Gea-Banacloche J, Jacobson S.
Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid.
J. Infect. Dis. 195: 450-4, 2007. [Journal]

9) Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I.
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Leukemia. 21: 169-74, 2007. [Journal]

10) Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemirli M.
Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma.
Am. J. Surg. Pathol. 31: 476-80, 2007. [Journal]

11) Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR.
Host T Cells Affect Donor T Cell Engraftment and Graft-versus-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Biol. Blood Marrow Transplant. 13: 1022-30, 2007. [Journal]

12) Stratton P, Turner ML, Childs R, Barrett J, Bishop M, Wayne AS, Pavletic S.
Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation.
Obstetrics and gynecology. 110: 1041-9, 2007. [Journal]

13) Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P, Mayberry H, Bishop MR, Childs R, Barrett AJ.
Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant. 38: 101-9, 2006. [Journal]

14) Hardy NM, Fowler DH, Bishop MR.
Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
Clin. Breast Cancer. 7: 87-9, 2006. [Journal]

15) O'Mahony D, Bishop MR.
Monoclonal antibody therapy.
Front. Biosci. 11: 1620-35, 2006. [Journal]

16) Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant. 12: 1150-60, 2006. [Journal]

17) Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn J, Bashey A, Bishop MR, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang M, Keating A, Weisdorf DJ, Horowitz MM.
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Biol. Blood Marrow Transplant. 12: 204-16, 2006. [Journal]

18) Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL.
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Biol. Blood Marrow Transplant. 12: 22-30, 2006. [Journal]

19) Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR.
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
Biol Blood Marrow Transplant. 11: 593-9, 2005. [Journal]

20) Sportès C, McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE.
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
Biol Blood Marrow Transplant. 11: 472-83, 2005. [Journal]

21) Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A.
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Am J Hematol. 78: 265-74, 2005. [Journal]

22) Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research.
J Clin Oncol. 23: 5788-94, 2005. [Journal]

23) Kwak LW, Neelapu SS, Bishop MR.
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
Semin Oncol. 31: 37-46, 2004. [Journal]

24) Dean RM, Bishop MR.
Allogeneic hematopoietic stem cell transplantation for lymphoma.
Clin Lymphoma. 4: 238-49, 2004. [Journal]

25) Bishop MR.
Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
Haematologica. 89: 599-605, 2004. [Journal]

26) Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R.
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
J Clin Oncol. 22: 3886-92, 2004. [Journal]

27) Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR.
Clinical.
Clin Gastroenterol Hepatol. 2: 237-45, 2004. [Journal]

28) Walshe J, Bishop MR.
Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning.
Cytotherapy. 6: 589-2, 2004. [Journal]

29) Fowler DH, Bishop MR, Gress RE.
Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.
Semin Oncol. 31: 56-67, 2004. [Journal]

30) Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, Fowler DH, Bishop MR, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs RW, Illei GG, Leitman SF, Malech HL, Horwitz ME.
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.
Blood. 103: 3986-8, 2004. [Journal]

31) Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH.
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Br J Haematol. 126: 837-43, 2004. [Journal]

32) Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, Childs R, Barrett AJ, Csaky KG.
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.
Bone Marrow Transplant. 33: 1031-5, 2004. [Journal]

33) Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA.
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Leukemia. 17: 499-514, 2003. [Journal]

34) Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Biol Blood Marrow Transplant. 9: 162-9, 2003. [Journal]

35) Dean RM, Bishop MR.
Graft-versus-host disease: emerging concepts in prevention and therapy.
Curr Hematol Rep. 2: 287-94, 2003. [Journal]

36) Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McGuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, Pavletic ZS.
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Cytotherapy. 5: 542-52, 2003. [Journal]

37) Bishop MR.
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
Clin Breast Cancer. 4: 39-45, 2003. [Journal]

38) Bishop MR.
The Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity?.
J Clin Oncol. 21: 3744-53, 2003. [Journal]

39) Khuu HM, Cowley H, David-Ocampo V, Carter CS, Kasten-Sportes C, Wayne AS, Solomon SR, Bishop MR, Childs RM, Read EJ.
Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences.
Cytotherapy. 4: 539-49, 2002. [Journal]

40) Knutson KL, Bishop MR, Schiffman K, Disis ML.
Immunotherapy for breast cancer.
Cancer Chemother Biol Response Modif. 20: 351-69, 2002. [Journal]

41) Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR.
Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
Bone Marrow Transplant. 29: 709-10, 2002. [Journal]

42) Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A, Bishop MR.
Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics.
Blood. 98: 1963-70, 2001. [Journal]

43) Sharp JG, Bishop MR, Copple B, Greiner TC, Iversen PL, Jackson JD, Joshi SS, Benner EJ, Mann SL, Rao AK, Vose JM.
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
Leuk Lymphoma. 42: 417-27, 2001. [Journal]

44) Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A.
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Blood. 96: 80-5, 2000. [Journal]

45) Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS.
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
Leuk Lymphoma. 37: 65-70, 2000. [Journal]

46) Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL.
Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
Bone Marrow Transplant. 26: 663-6, 2000. [Journal]

47) Mata JE, Bishop MR, Tarantolo SR, Angel CR, Swanson SA, Iversen PL.
Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.
J Toxicol Clin Toxicol. 38: 383-7, 2000. [Journal]

48) Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, Zacharias D, Armitage JO, Kessinger A.
Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation.
J Clin Oncol. 18: 2269-72, 2000. [Journal]

49) McCarthy NJ, Bishop MR.
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
Oncologist. 5: 487-96, 2000. [Journal]

50) Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, Kollath JP, Weisenburger DD, Kessinger A, Wolff SN, Armitage JO, Bishop MR.
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
Bone Marrow Transplant. 25: 717-22, 2000. [Journal]

51) Mata JE, Jackson JD, Joshi SS, Tracewell WG, Pirruccello SJ, Murphy BJ, Bishop MR, Iversen PL.
Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine.
J Hematother Stem Cell Res. 9: 205-14, 2000. [Journal]

This page was last updated on 9/30/2008.